Disclosure
CAI summary · Not investment advice
Curiox Biosystems' Q3 2026 consolidated revenue was KRW 1,492 million, up 7.73% year over year and 26.87% quarter over quarter, with an operating loss of KRW 3,960 million.
Commentary
AI commentary · Not investment advice
What happened
Curiox Biosystems released its provisional consolidated results for the third quarter of 2026, covering July 1 to September 30, as a fair disclosure. Revenue was KRW 1.5 billion, operating profit was KRW -4.0 billion, and net profit was KRW -5.4 billion. The filing was received on October 27, 2026.
In the company's terms
Against the previous quarter, revenue rose 26.87% from KRW 1.2 billion to KRW 1.5 billion. Operating profit moved 11.15%, from KRW -4.5 billion to KRW -4.0 billion, and net profit moved -10.51%, from KRW -4.8 billion to KRW -5.4 billion. Against the same quarter a year earlier, revenue rose 7.73% from KRW 1.4 billion. Operating profit changed by -47.76% from KRW -2.7 billion, and net profit by -76.57% from KRW -3.0 billion. The materials list a figure of -0.4% relative to market capitalization.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist